Deep Sequencing of Hepatitis B Virus Reveals Clinically Relevant Low-Frequency Variants Among People Living with HIV in Botswana
(1) Background: The Hepatitis B virus (HBV) is characterized by extensive genetic diversity, including low-frequency variants that contribute to disease progression. We aimed to characterize low-frequency variants and evaluate their potential clinical impact. (2) Methods: We utilized 104 HBV near-full-length sequences generated using next-generation sequencing (NGS) from people living with HIV (PLHIV). We used an in-house bioinformatics suite (HBVgenomeR v5.9.7) to filter for low-frequency variants (5–50%), which were compared to escape and drug resistance mutations (DRMs) and hepatocellular carcinoma (HCC)-associated mutations reported at the consensus level. Unclassified variants were characterized by HBV open reading frames (ORFs) to determine mutation frequency per genomic region. (3) Results: A total of six escape mutations were detected in 8/104 (7.7%) sequences, with surfaceN131T being the most prevalent (5/8). We also observed six DRMs in 30/104 (28.8%), with rtV173L being the most prevalent (21/30). Truncation mutations were also observed with rtA181T/sW172* and rtM204I/sW196L being the most prevalent. A total of 8/104 (7.7%) sequences had four variants associated with HCC. The xP46S was the highest observed HCC-associated mutation at 5/8. We report 1152 unique uncharacterized variants across all ORFs, and these were found in 94/104 (90.4%) sequences. The RNaseH domain had the highest burden (330/1152, 28.6%). (4) Conclusions: Deep sequencing results identified clinically significant mutations, including those below the 20% detection limit of traditional sequencing, that would go unreported. This highlights the possible underreporting of mutational burden in people living with HBV/HIV, indicating the importance of deep sequencing to aid in HBV/HIV understanding and management.
Authors
- Kabo Baruti (ORCID: https://orcid.org/0000-0002-1592-7533)
- Bonolo Bonita Phinius (ORCID: https://orcid.org/0000-0002-0180-2705)
- Simani Gaseitsiwe (ORCID: https://orcid.org/0000-0002-7089-3735)
- Gorata G. A. Mpebe (ORCID: https://orcid.org/0009-0004-1153-2480)
- Wonderful Tatenda Choga (ORCID: https://orcid.org/0000-0001-7606-0569)
- Mosimanegape Jongman (ORCID: https://orcid.org/0000-0002-6454-3173)
- Motswedi Anderson (ORCID: https://orcid.org/0000-0001-9974-9684)
- Sikhulile M. Moyo (ORCID: https://orcid.org/0000-0003-3821-4592)
- Tsholofelo Ratsoma (ORCID: https://orcid.org/0009-0006-9815-9088)
- Linda Mpofu-Dobo (ORCID: https://orcid.org/0009-0000-8833-1805)
- Patience Motshosi
- Chanana Dorcus Tsayang (ORCID: https://orcid.org/0009-0009-4069-7176)
- Goabaone Mbae
- Florence G. Gaongalelwe
- Basetsana Katlo S. Phakedi
Institutions
- Harvard University (US)
- University of Zimbabwe (ZW)
- University of Botswana (BW)
- Botswana International University of Science and Technology (BW)
- The Francis Crick Institute (GB)
- National University of Science and Technology (ZW)
- Africa Health Research Institute (ZA)
- Botswana Harvard AIDS Institute Partnership (BW)
- University of Pretoria (ZA)
Publication Details
- Journal
- Viruses
- Published
- 2026-08-17
- DOI
- https://doi.org/10.3390/v18080904
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- Fogarty International Center